We are live on
!
Find out more
RPAM
Rhenman & Partners Asset Management Portfolio holdings
AUM
$810M
1-Year Est. Return
30.2%
This Fund
S&P 500
This Quarter
Est. Return
+5.87%
1 Year Est. Return
+30.2%
3 Year Est. Return
+116.38%
5 Year Est. Return
+153.13%
10 Year Est. Return
+962.25%
AUM
$833M
AUM Growth
+$240M
(+40%)
Cap. Flow
+$158M
Cap. Flow
% of AUM
18.98%
Top 10 Holdings %
Top 10 Hldgs %
35.14%
Holding
103
New
14
Increased
42
Reduced
34
Closed
7
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$19.1M |
| 2 |
UnitedHealth
UNH
|
+$11.9M |
| 3 |
Cooper Companies
COO
|
+$7.39M |
| 4 |
ESRX
Express Scripts Holding Company
ESRX
|
+$6.9M |
| 5 |
Medtronic
MDT
|
+$6.56M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Amgen
AMGN
|
+$4.81M |
| 2 |
OCR
OMNICARE INC
OCR
|
+$3.85M |
| 3 |
Gilead Sciences
GILD
|
+$3.17M |
| 4 |
Ligand Pharmaceuticals
LGND
|
+$3.01M |
| 5 |
McKesson
MCK
|
+$3.01M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 76.95% |
| 2 | Financials | 0.78% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1
PUT
iShares S&P 100 ETF
OEF
$20.1B
| $73.8M | 8.86% |
+200,000
| New | +$18.5M |
|
2
PUT
State Street Health Care Select Sector SPDR ETF
XLV
$41.9B
| $52.1M | 6.25% |
+700,000
| New | +$51.9M |
|
|
3
UnitedHealth
UNH
$376B
| $28.2M | 3.38% |
231,000
+101,000
| +78% | +$11.9M |
|
|
ALXN
4
DELISTED
Alexion Pharmaceuticals
ALXN
| $24M | 2.88% |
132,800
+17,822
| +16% | +$3.08M |
|
5
Alkermes
ALKS
$8.22B
| $22.5M | 2.7% |
349,000
+91,000
| +35% | +$5.57M |
|
6
Biogen
BIIB
$30B
| $20.3M | 2.44% |
50,291
+9,591
| +24% | +$3.85M |
|
7
CVS Health
CVS
$133B
| $19.3M | 2.32% |
184,000
+39,000
| +27% | +$3.98M |
|
|
8
Johnson & Johnson
JNJ
$618B
| $18.6M | 2.24% |
+191,000
| New | +$19.1M |
|
9
Cardinal Health
CAH
$53.9B
| $18M | 2.16% |
215,000
+73,600
| +52% | +$6.5M |
|
|
CELG
10
DELISTED
Celgene Corp
CELG
| $15.9M | 1.9% |
137,000
-14,000
| -9% | -$1.6M |
|
11
AbbVie
ABBV
$443B
| $15.7M | 1.88% |
233,000
+13,000
| +6% | +$849K |
|
|
12
Gilead Sciences
GILD
$162B
| $15.2M | 1.83% |
130,000
-29,000
| -18% | -$3.17M |
|
|
RAD
13
DELISTED
Rite Aid Corporation
RAD
| $15.2M | 1.82% |
90,850
+27,027
| +42% | +$4.54M |
|
14
Merck
MRK
$322B
| $14.8M | 1.78% |
272,480
-41,920
| -13% | -$2.35M |
|
15
Eli Lilly
LLY
$1.02T
| $14.6M | 1.75% |
175,000
+46,000
| +36% | +$3.51M |
|
16
Bristol-Myers Squibb
BMY
$133B
| $13.2M | 1.58% |
198,000
+69,000
| +53% | +$4.55M |
|
|
AGN
17
DELISTED
Allergan plc
AGN
| $12.7M | 1.53% |
42,000
-3,300
| -7% | -$984K |
|
18
BioMarin Pharmaceuticals
BMRN
$11.6B
| $12.6M | 1.51% |
92,000
+17,000
| +23% | +$2.11M |
|
19
Jazz Pharmaceuticals
JAZZ
$15.9B
| $12.3M | 1.48% |
70,000
+15,000
| +27% | +$2.69M |
|
20
Nektar Therapeutics
NKTR
$2.39B
| $11.7M | 1.41% |
62,467
-3,973
| -6% | -$684K |
|
|
21
Medtronic
MDT
$109B
| $11.5M | 1.38% |
154,800
+85,800
| +124% | +$6.56M |
|
22
Incyte
INCY
$24.2B
| $11.2M | 1.35% |
107,502
-12,498
| -10% | -$1.29M |
|
|
23
Amgen
AMGN
$208B
| $10.6M | 1.27% |
69,000
-30,000
| -30% | -$4.81M |
|
24
Regeneron Pharmaceuticals
REGN
$78.5B
| $9.69M | 1.16% |
19,000
-3,000
| -14% | -$1.46M |
|
|
CEMP
25
DELISTED
Cempra, Inc.
CEMP
| $9.52M | 1.14% |
277,161
+91,861
| +50% | +$3.25M |
|
Similar funds
BBI
SSG
PS
ACM
AR
DWA
SLG
KCP
Rhenman & Partners Asset Management's Q2 2015 Portfolio in Review
As of Q2 2015, Rhenman & Partners Asset Management held 103 positions worth $833M, up 40% from $593M the previous quarter. Its ten largest holdings account for 35% of the portfolio.
Rhenman & Partners Asset Management deployed $158M of net new capital in Q2 2015, opening 14 new positions and adding to 42 existing holdings. Its largest new stake was Johnson & Johnson: 191,000 shares worth $18.6M.
By sector, the portfolio is most concentrated in Healthcare at 77% of assets, down from 84% a quarter earlier, followed by Financials.
On the sell side, the largest reduction was Amgen, an estimated $4.81M trimmed.
- Rhenman & Partners Asset Management's largest Q2 2015 buy was Johnson & Johnson: 191,000 shares worth $18.6M.
- Rhenman & Partners Asset Management added most to UnitedHealth in Q2 2015, an estimated $11.9M increase.
- Rhenman & Partners Asset Management's biggest Q2 2015 reduction was Amgen, cutting an estimated $4.81M.
- Rhenman & Partners Asset Management fully exited OMNICARE INC in Q2 2015, selling an estimated $3.85M.
- Rhenman & Partners Asset Management's ten largest holdings make up 35% of its $833M portfolio in Q2 2015.
- Rhenman & Partners Asset Management opened 14 new positions and closed 7 in Q2 2015.
- Rhenman & Partners Asset Management's portfolio value rose 40% quarter-over-quarter to $833M.
Based on Rhenman & Partners Asset Management's 13F filing for Q2 2015, filed 30 Jul 2015.